Welcome to our dedicated page for AtriCure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on AtriCure stock.
AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.
The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.
AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.
Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.
For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.
AtriCure, Inc. (NASDAQ: ATRC) reported preliminary financial results for Q4 and full year 2021, showing approximately
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), will participate in the 40th Annual J.P. Morgan Healthcare Conference. Management's presentation is scheduled for January 10, 2022, at 7:30 a.m. ET. Investors can access the live audio webcast through the company’s website. AtriCure specializes in innovative technologies for Afib management, including the FDA-approved Isolator® Synergy™ Ablation System, and widely used AtriClip® devices for left atrial appendage management. For more details, visit AtriCure.com.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A prerecorded fireside chat is scheduled for November 22, 2021, accessible via the company's website. Additionally, management will hold investor meetings on December 1, 2021. AtriCure focuses on innovative technologies for Afib management, impacting over 33 million people globally, with notable products including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.
AtriCure, a leader in atrial fibrillation treatments, reported strong Q3 2021 results with revenues of $70.5 million, a 28.7% increase year-over-year. U.S. revenue rose to $57.5 million due to stable cardiac procedures and high demand for Cryo Nerve Block and Hybrid AF therapy products. However, worldwide revenue fell by 1.3% from Q2 2021. Gross profit reached $52.2 million, with a gross margin of 74.1%. The company maintains its 2021 revenue guidance of $270-$275 million and adjusted EBITDA loss of approximately $10 million.
AtriCure, Inc. (NASDAQ: ATRC) announces participation in upcoming investor conferences, presenting at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. Eastern Time. A live audio webcast will be available on the company's website. Additionally, AtriCure will host investor meetings at the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. AtriCure focuses on innovative surgical solutions for atrial fibrillation and left atrial appendage management, with devices like the FDA-approved Isolator® Synergy™ Ablation System.
AtriCure, a leader in atrial fibrillation (Afib) treatments, has announced the release of its third quarter 2021 financial results on November 3, 2021. A conference call will take place at 4:30 p.m. ET to discuss these results, which can be accessed via phone or through a live audio webcast. AtriCure's technologies, including the Isolator® Synergy™ Ablation System and AtriClip® products, are critical in treating over 33 million people affected by Afib globally. These innovations position AtriCure as a prominent player in the medical device market.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The presentation is set for Tuesday, September 14, 2021, at 11:45 a.m. Eastern Time. Attendees can access a live or archived audio webcast via the Investors section of AtriCure's website. AtriCure innovates treatments for Afib, impacting over 33 million people worldwide, and offers products like the Isolator® Synergy™ Ablation System and AtriClip® LAA management devices.
AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter 2021, with revenue reaching $71.4 million, up 74.8% from the previous year. U.S. revenue saw a significant increase of 78.4% to $60.1 million, driven by recovery in cardiac procedures following COVID-19 disruptions. The company received FDA approval for the EPi-Sense® System, enhancing its treatment offerings. Adjusted EBITDA loss improved to $2.7 million. The 2021 revenue guidance has been updated to $270 to $275 million, reflecting 31% to 33% growth, although pandemic uncertainties remain a concern.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the Canaccord 41st Annual Growth Conference. The company will present on August 11, 2021, at 8:00 a.m. Eastern Time. Interested participants can access the live and archived audio webcast on AtriCure’s website. AtriCure is known for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® for left atrial appendage management, addressing the needs of over 33 million Afib sufferers globally.
AtriCure, Inc. (Nasdaq: ATRC) has announced the release date for its second quarter 2021 financial results, set for August 4, 2021. A conference call will take place at 4:30 p.m. ET on the same day, allowing stakeholders to discuss the results. AtriCure specializes in innovative treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, with its technologies widely used by healthcare professionals. The company aims to improve outcomes for the over 33 million people affected by Afib globally.
FAQ
What is the current stock price of AtriCure (ATRC)?
What is the market cap of AtriCure (ATRC)?
What does AtriCure, Inc. specialize in?
What is the Isolator® Synergy™ Ablation System?
What is AtriClip?
How does AtriCure distribute its products?
What types of products does AtriCure offer?
Where does AtriCure generate most of its revenue?
Are AtriCure’s products used internationally?
What makes AtriCure's products unique?
Where can I find more information about AtriCure?
What are AtriCure’s latest achievements?
